Cargando…
TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma
Chondrosarcomas are the second most common malignant bone tumor. Activating promoter mutations in telomerase reverse transcriptase (TERT) was recently described by us and others as a frequent mutation in high-grade chondrosarcoma. In this study, we investigate the prognostic significance of TERT pro...
Autores principales: | Zhang, Yifan, Chen, Yi, Yang, Chen, Seger, Nelly, Hesla, Asle C., Tsagkozis, Panagiotis, Larsson, Olle, Lin, Yingbo, Haglund, Felix |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514332/ https://www.ncbi.nlm.nih.gov/pubmed/34108637 http://dx.doi.org/10.1038/s41379-021-00848-0 |
Ejemplares similares
-
Transcriptome profiling of Ewing sarcomas – treatment resistance pathways and IGF‐dependency
por: Chen, Yi, et al.
Publicado: (2020) -
Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas
por: Zhang, Yifan, et al.
Publicado: (2022) -
Current Status of Management and Outcome for Patients with Ewing Sarcoma
por: Hesla, Asle Charles, et al.
Publicado: (2021) -
Clear‐cell chondrosarcomas: Fine‐needle aspiration cytology, radiological findings, and patient demographics of a rare entity
por: Zhang, Yifan, et al.
Publicado: (2020) -
Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
por: Hesla, Asle Charles, et al.
Publicado: (2020)